^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    relacorilant (CORT125134)

    i
    Other names: CORT125134, CORT-125134, CORT 125134
    Company:
    Corcept Therap
    Drug class:
    GCR antagonist
    Related drugs:
    17h
    Gynecologic cancers in 2025: a year in review. (PubMed, Int J Gynecol Cancer)
    In advanced ovarian cancer, TRUST re-examined surgical timing, supporting primary cytoreduction in selected resectable patients, whereas ICON8B suggested that weekly paclitaxel with carboplatin and bevacizumab may improve outcomes in high-risk disease. Platinum-resistant ovarian cancer saw the most disruptive progress: mirvetuximab soravtansine validated folate receptor-α as a therapeutic target, with overall survival benefit in high-expressing tumors; trastuzumab deruxtecan expanded actionable HER2 disease, with greatest activity in tumors rated 3+ by immunohistochemistry; and combination strategies, including relacorilant plus nab-paclitaxel and pembrolizumab plus weekly paclitaxel ± bevacizumab, delivered clinically meaningful survival signals, underscoring the need for harmonized biomarker strategies and proactive toxicity mitigation...In cervical cancer, pembrolizumab added to definitive chemoradiotherapy set a new benchmark in locally advanced disease, and ultra-sensitive circulating tumor DNA analyses emerged as a powerful prognostic tool to enable post-treatment risk-adapted strategies. Collectively, the 2025 data set reinforces a "right therapy, right patient, right time" paradigm and prioritizes confirmatory antibody-drug conjugate trials, resistance biology, and dynamic biomarkers to translate gains into durable, equitable benefit.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha )
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • albumin-bound paclitaxel • Elahere (mirvetuximab soravtansine-gynx) • relacorilant (CORT125134)
    2ms
    Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • albumin-bound paclitaxel • relacorilant (CORT125134)
    3ms
    BELLA: Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (clinicaltrials.gov)
    P2, N=270, Recruiting, Corcept Therapeutics | N=90 --> 270
    Enrollment change
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    9ms
    Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=178, Completed, Corcept Therapeutics | Active, not recruiting --> Completed
    Trial completion • Platinum resistant
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    9ms
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Corcept Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    10ms
    Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Corcept Therapeutics
    New P2 trial
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • relacorilant (CORT125134)
    11ms
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=381, Active, not recruiting, Corcept Therapeutics | Trial primary completion date: Mar 2026 --> Mar 2025
    Trial primary completion date
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    11ms
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=381, Active, not recruiting, Corcept Therapeutics | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    12ms
    IRB22-1318: A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, University of Chicago | Trial completion date: Apr 2029 --> Apr 2028 | Trial primary completion date: Oct 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    Xtandi (enzalutamide) • relacorilant (CORT125134)
    1year
    Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, Corcept Therapeutics | Enrolling by invitation --> Active, not recruiting | N=75 --> 125
    Enrollment closed • Enrollment change
    |
    relacorilant (CORT125134)
    1year
    GRADIENT: Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas (clinicaltrials.gov)
    P3, N=137, Completed, Corcept Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    relacorilant (CORT125134)
    1year
    New Trends in Treating Cushing's Disease. (PubMed, touchREV Endocrinol)
    At the pituitary level, pasireotide is an approved somatostatin receptor ligand, and compounds targeting cell cycle regulation, cell signalling and epigenetics are now under investigation. Levoketoconazole and osilodrostat are novel steroid inhibitors, and relacorilant overcomes the adverse effects of mifepristone. Adrenal ACTH receptor blockage and immunotherapy could also play a role.
    Journal
    |
    SSTR (Somatostatin Receptor)
    |
    relacorilant (CORT125134) • Signifor (pasireotide) • Mifeprex (mifepristone)